Kymera (KYMR) CEO Mainolfi exercises options and sells 30,000 shares under 10b5-1 plan
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Kymera Therapeutics, Inc. director and CEO Nello Mainolfi reported an exercise-and-sell transaction in Kymera common stock. On April 29, 2026, he exercised stock options to acquire 30,000 shares at $2.08 per share and then sold 30,000 shares of common stock in open-market trades.
The sales were split into blocks of 936, 12,059, and 17,005 shares at weighted average prices of about $82.45, $81.70, and $80.74. According to the filing, these trades were executed under a pre-arranged Rule 10b5-1 trading plan. After the transactions, Mainolfi directly held 666,195 shares of Kymera common stock.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 30,000 shares ($2,435,377)
Net Sell
5 txns
Insider
Mainolfi Nello
Role
Chief Executive Officer
Sold
30,000 shs ($2.44M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 30,000 | $0.00 | -- |
| Exercise | Common Stock | 30,000 | $2.08 | $62K |
| Sale | Common Stock | 17,005 | $80.74 | $1.37M |
| Sale | Common Stock | 12,059 | $81.70 | $985K |
| Sale | Common Stock | 936 | $82.45 | $77K |
Holdings After Transaction:
Stock Option (Right to Buy) — 215,559 shares (Direct, null);
Common Stock — 696,195 shares (Direct, null)
Footnotes (1)
- These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 6, 2024 adopted by the reporting person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.23 to $81.215, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.23 to $82.18, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.30 to $83.07, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The shares underlying this stock option are fully vested and exercisable.
Key Figures
Shares sold: 30,000 shares
Option exercise size: 30,000 shares
Exercise price: $2.08/share
+5 more
8 metrics
Shares sold
30,000 shares
Total Kymera common shares sold on April 29, 2026
Option exercise size
30,000 shares
Stock options exercised into Kymera common stock on April 29, 2026
Exercise price
$2.08/share
Strike price of stock options exercised by CEO
Sale price block 1
$82.45/share
Weighted average price for 936 shares of Kymera common stock sold
Sale price block 2
$81.70/share
Weighted average price for 12,059 shares of Kymera common stock sold
Sale price block 3
$80.74/share
Weighted average price for 17,005 shares of Kymera common stock sold
Post-transaction holdings
666,195 shares
Kymera common shares directly held by CEO after transactions
Option expiration
November 13, 2029
Expiration date of the stock option exercised
Key Terms
Rule 10b5-1 trading plan, weighted average price, Stock Option (Right to Buy), derivative security, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 6, 2024"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Stock Option (Right to Buy) financial
"security_title": "Stock Option (Right to Buy)""
derivative security financial
"transaction_code_description": "Exercise or conversion of derivative security""
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
Common Stock financial
"security_title": "Common Stock""
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
FAQ
What insider transaction did Kymera Therapeutics (KYMR) report for Nello Mainolfi?
Kymera Therapeutics reported that CEO Nello Mainolfi exercised options for 30,000 shares at $2.08 and sold 30,000 common shares in open-market trades. The filing shows this as an exercise-and-sell pattern rather than a pure purchase or sale.
What is the option exercise disclosed for Kymera (KYMR) CEO Nello Mainolfi?
The filing shows Mainolfi exercised stock options covering 30,000 Kymera common shares at an exercise price of $2.08 per share. These options were fully vested and exercisable, and the exercise coincided with same-day sales of an equal number of common shares.
Were Kymera (KYMR) CEO Nello Mainolfi’s reported sale prices single trades or averages?
The reported sale prices are weighted averages. Footnotes explain that the Kymera shares were sold in multiple trades within price ranges, for example $80.23 to $81.215, and that detailed price breakdowns are available on request from relevant parties.